Abstract 271P
Background
High grade B cell lymphomas (HGBCL) are aggressive lymphomas, grouped into two entities according to whether or not they express double hit/double expresser phenotype. Entity without double hit/expresser phenotype is termed as HGBCL NOS. Best therapeutic approach to patients with HGBCL NOS is not known; treated with either regimens ideal for DLBCL or with more intensive Burkitt’s like regimens.
Methods
Hospital records of patients diagnosed with HGBCL NOS were retrieved. 34 patients had been non randomly assigned to receive CHOP like regimens (CHOP [20], COP [2], CHOP+HD MTX [5]) or dose adjusted (DA) EPOCH [7] with or without Rituximab[13]. Response rate (RR) to chemoimmunotherapy, toxicity profiles, PFS at 20 months of follow up and OS were noted.
Results
76.4 %(26) were diagnosed with advanced stage. 76.4%(26) had extra-nodal involvement. overall RR to first line therapy was 100%( CR = 58.8%, PR = 29.4%, SD = 11.8%). 48.1% CR and 37.0% PR in the CHOP like regimen arm and 100% CR rate in patients receiving DAEPOCH. At 20 months follow up, the mean and median PFS was 14.8 months and 11 months. DAEPOCH was associated with highest mean and median PFS (23.7 and 30 months) and same for CHOP were (10.31 and 9 months) at 20months of follow up(p = 0.039). Median OS not reached at 20 months of follow up. Use of Rituximab was associated with improved median PFS (30m vs 10m; p = 0.038) at 20 months, in univariate analysis. On an average 1.54 episodes of grade 3-4 neutropenia and 0.65 episodes of febrile neutropenia occurred per patient. Corresponding values for DAEPOCH and CHOP like regimens were (3.7 , 1.5) and ( 0.92, 0.40). 2(5.88%)cases had treatment related death, one each in DAEPOCH(14.2%) and CHOP like regimen arm (3.7%) arm. 21(61.76%) patients relapsed at one year.
Conclusions
Regimens like CHOP or DAEPOCH with Rituximab has high response rates but substantial proportion of patients may relapse. Grade 3-4 neutropenia occurs more frequently with DAEPOCH than CHOP, but treatment related mortality is low for both the regimens. Good PS patients do tolerate intensive regimens. Intensive regimens may be associated with longer PFS that may lead to longer OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract